NGNE vs. ORGO, HRTX, BMEA, ADCT, CRBP, IGMS, MRSN, RVNC, CDMO, and TRDA
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Organogenesis (ORGO), Heron Therapeutics (HRTX), Biomea Fusion (BMEA), ADC Therapeutics (ADCT), Corbus Pharmaceuticals (CRBP), IGM Biosciences (IGMS), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Avid Bioservices (CDMO), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical preparations" industry.
Neurogene (NASDAQ:NGNE) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Organogenesis has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Organogenesis has a net margin of 1.14% compared to Neurogene's net margin of 0.00%. Organogenesis' return on equity of 1.81% beat Neurogene's return on equity.
52.4% of Neurogene shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 1.6% of Neurogene shares are owned by company insiders. Comparatively, 34.0% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Neurogene presently has a consensus target price of $49.00, suggesting a potential upside of 63.55%. Organogenesis has a consensus target price of $4.83, suggesting a potential upside of 105.67%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Neurogene.
Organogenesis received 89 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 66.21% of users gave Organogenesis an outperform vote.
In the previous week, Neurogene had 2 more articles in the media than Organogenesis. MarketBeat recorded 2 mentions for Neurogene and 0 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.00 beat Neurogene's score of -0.31 indicating that Organogenesis is being referred to more favorably in the news media.
Neurogene has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Summary
Organogenesis beats Neurogene on 12 of the 17 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
